bioprocessing matters, august 2011 - university college · pdf fileconditions within a...

UCL ADVANCED CENTRE FOR BiOChEmiCAL ENgiNEERiNg

ISSUE SEVEN | AUGUST 2011

In this issue

IMRC for Bioprocessing Phase 3IChemE Accreditation:

Skilled Biochemical EngineersVision 2011: Senior Leadership Course

EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies

Responsive Bioprocessing Facility Completion

Bioprocess BriefingsSME Engagement: Immbio

In this issue

IMRC for Bioprocessing Phase 3ChemE Accreditation:





In this issue

IMRC for Bioprocessing Phase 3IChemE Accreditation:





ISSUE SEVEN | AUGUST 2011ISSUE SEVEN | AUGUST 2011

ContentsEditorial 2

Departmental news 3

Skilled Biochemical Engineers 6

Vision 2011 Senior Leadership Course 8

EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies 11

Responsive Bioprocessing Facility – Planning for the Future 12

Bioprocess Briefings 13

SME Engagement: Immbio Case Study 14

MBI® Module: Principles of Fermentation (3–5 October 2011) 15

MBI® course dates 2011–12 16

EditorialForeword by Professor Nigel Titchener-Hooker

Welcome to this seventh edition of BioProcessing Matters. Against a backdrop of radical changes to funding of

undergraduate students it is good to be able to report that UCL Biochemical Engineering continues to develop its portfolio of programmes and to demonstrate the quality and relevance of these. Furthermore, as funds for research become yet more focused it is important that we continue to win support for our research vision and initiatives in knowledge exchange.

This particular issue of BioProcessing Matters provides a snapshot of departmental activities and plans over the past months. Many of the outcomes are a result of years of careful planning and represent the culmination of significant team efforts. This is very much our ethos – to be a team focused on creating the individuals skilled in the very latest advances and methods needed for this key industry. These are big challenges but as you read through the following examples I believe it is clear that UCL Biochemical Engineering is rising to each of them.

Prof. Nigel Titchener-HookerHead of Department and Director of the Advanced Centre for Biochemical Engineering

2

Departmental news

Providing access to our research outputs through refereed publicationsOur publications list 2006–2010 is available in hard copy and highlights our ‘best picks’. Additionally, we have a more extensive list of 2002–2010 publications available as a Word document with embedded hyperlinks to the online publications. If you would like to receive a copy of either, please contact Dr Karen Smith ([email protected]).

IMRC for Bioprocessing Phase 3A key output of the EPSRC Innovative Manufacturing Research Centre (IMRC) for Bioprocessing has been the discovery and development of ultra-scale-down devices and methods designed to provide new insights and solutions of the challenges for processing of next generation biological materials. Examples of such ultra scale-down methods are shown on page 7 and on page 14..

All stages from fermentation and cell culture to primary recovery to purification to formulation and finishing have been addressed within the IMRC. This has been a result of ten years’ collaboration with industrial experts (over 40 companies have been involved) and academic experts within and outside UCL.

The main UCL players in this activity have been:Dr Frank Baganz (fermentation and cell culture) •Dr Dan Bracewell (primary recovery and chromatography) •Dr Paul Dalby (protein engineering and formulation) •Dr Suzy Farid (decision-support tools)•Prof. Eli Keshavarz-Moore (cell bioprocessing) •Prof. Mike Hoare (whole bioprocess ultra scale-down and primary recovery) •Prof. Gary Lye (microbiochemical engineering and industrial biotechnology) •Prof. Chris Mason (regenerative medicine bioprocessing)•Dr Martina Micheletti (cell culture microwell engineering) •Dr Tarit Mukhopadhyay (vaccine bioprocessing ) •Dr Darren Nesbeth (synthetic biology bioprocessing) •Dr Karen Smith (knowledge transfer) •Prof. Nigel Titchener-Hooker (whole bioprocess analysis) •Dr Ivan Wall (regenerative medicines bioprocessing) •Prof. John Ward (cell engineering) •Dr Yuhong Zhou (bioprocessing data acquisition)•

3

We are now entering the third phase of the IMRC. This is focused on establishing the use of ultra-scale-down technologies in the bioprocessing industries, not only for biopharmaceuticals but also vaccines, stem cell therapies and products of industrial biotechnology.

We would like to express our thanks to the EPSRC and to our industrial collaborators for their support and to Management Committee Members (Chair Prof. John Mann) and the Steering Group (Chair Richard Francis) for giving their time and invaluable insights..

Hard copies of our 2011 Report are now available to IMRC member companies. A downloadable pdf version is also available via our IMRC web portal at www.ucl.ac.uk/biochemeng/industry/imrc.

For more information about IMRC Phase 3, please contact Prof Mike Hoare at [email protected].

Industrial Training Open Day SuccessWe held our annual Industrial Training Day on 14 March and, as usual, attracted a superb range of attendees from industry. Representatives from a wide range of companies such as BP, GSK, MedImmune, Pfizer and UCB enjoyed hearing about our latest training initiatives at undergraduate, postgraduate and post-experience levels and had an opportunity to meet our students at a well-received Poster Session in the afternoon. The BPL-sponsored Poster Prize this year went to Kane Miller for his poster entitled Design and Evaluation of an Internally Radiating Photobioreactor for Generic Application of Algal-Based Production Systems.

Suzy Farid FIChemECongratulations to Dr Suzy Farid (pictured, right) on becoming a Fellow of the Institution of Chemical Engineers. In order to become a Fellow one must be an engineering professional of distinction, making a significant contribution to one’s profession – an excellent description of Suzy. There is also a requirement to show technical excellence and leadership of peers which Suzy has repeatedly demonstrated.

Clive Osborn RetiresAfter an incredible 40 years with the Department, we say goodbye to Clive Osborn, our Facilities Manager, who retired this Spring. Clive saw the department grow from the cramped conditions within a retrofitted pilot plant (where he worked as a technician

4

5

on a research grant) to the purpose-designed facilities of the ACBE which he very ably managed with his team of technical experts. Generations of student researchers as well as numerous academic staff benefited from Clive’s professionalism and his huge knowledge of bioprocessing. Most crucially Clive developed an intimate knowledge of all the support infrastructure necessary for the effective functioning of a state-of-the-art facility. Cheerful even when faced with apparent calamities such as collapsed ceilings due to ruptured water pipes, Clive was ingenious in securing the best possible help from central College support. Clive helped to realise the research and training goals that now characterise the department. We are not quite sure what Clive has planned but we wish him the very best of good fortune in his retirement. Gareth Mannell takes over the role.

IChemE BursaryWe are delighted that one of our third year students, Asma Ahmad, has won an IChemE Pharma Group summer research bursary. She will work with PhD student Ebenezer Ojo and Prof. Gary Lye on ‘Parallel Evaluation of Algae for Sustainable Production of Biopharmaceuticals Using Miniature Photobioreactors’ .

The project aims to explore recombinant protein production in algae. Algae represent a relatively unexplored alternative to current microbial and mammalian expression systems. Potentially they offer a number of significant advantages including cheaper manufacture (simple defined media), sustainable and environmentally friendly processes and increased safety (lack of contamination with human viruses).

This bursary will give Asma the opportunity of an extended period of hands-on experimentation and experience of independent experimental design. It will also provide her with valuable laboratory skills in analysis and cell culture (these complement the pilot plant processing skills she has already gained during her MEng programme). The numerical aspects of the project will also enable her to apply biochemical engineering principles to the modelling of biological systems.

Bang Goes the TheoryMike Hughson, an Research Engineer in the Industrial Doctoral Training Centre, is also our resident ‘NOISEmaker’ (New Outlooks in Science & Engineering) for the EPSRC. He was recruited last year as one of their ambassadors of science; he received media and public engagement training and he’s passionate about getting more people interested in science at A-level and university level.

He has been interviewed about vaccines by Phil Kennedy on Radio Berkshire’s ‘Drive Time’, done a live Q&A blog for The Guardian regarding careers in biological research and, most recently, appeared as an extra on Bang Goes The Theory, a BBC 1 programme that was part of a citizen science campaign to get the general public involved in taking measurements and sending them into whoever needs the data – in this case, the Met Office.

© UCL Media Services, All Rights Reserved

6

Skilled Biochemical EngineersUCL Biochemical Engineering has just been re-awarded accreditation status for its training of Undergraduate and Masters-level students of biochemical engineering. This means that 80+ students graduating each year from the Department are eligible to go on and gain Chartered Engineer status (CEng, MIChemE).

Why is this important now?For the contract engineering sector of the bioprocessing industry this is the key professional qualification for practising engineers. However, for all other parts of the bioprocessing sector this is a crucial skill, and we are increasingly seeing our graduates being required to take up Chartered Engineer status even when working in research and development as well as in manufacture and design.

Chartered Engineer status confirms a skill basis and a rigorous understanding of how best to translate new biological and life science discoveries into real process outcomes. Success means not only cost-effective production of therapies and other biological products but also robust processing which meets all the necessary safety and regulatory validation standards and achieves product quality by design.

Why is this important for the future?The need for safe, robust and economical processes designed and delivered by biochemical engineers of the future are probably even more important for the successful delivery of the next generation targets with which we are faced, such as engineered proteins, stem cells, new vaccines and so-called cell factories, produced as a result of synthetic biology. These and many other similar challenges are central features of new aspects of biochemical engineering, sometimes described as biological engineering.

How can you help?The bioprocessing sector is one of most challenging of industries in which to turn the promise of new discoveries into benefits for society. A wide range of high-level skills are needed. One of the key skills is biochemical engineering.

There are literally thousands of UCL graduate biochemical engineers working in your industries. The industrial experience they gain with you means they are qualified to claim Chartered Engineer status. By doing so they gain important status in dealing with professional bodies such as FDA, EMEA and HSE, as well as with colleagues in the industry network required to deliver new products to society.

We are seeing an increasing number of companies in the bioprocessing sector

encouraging the uptake of chartered engineering status as an important career move.When you next bump into one of our graduates why not ask them if they have gained chartered engineering status?

If they haven’t, tell them to get back in touch with us and we will provide the help and advice needed.

What’s in it for all of us?The more we can raise the profile of professional biochemical engineers the more we will be able to create the community and support to help meet the demand for skilled bioprocessing experts needed to deliver benefits of the advances in the life, biomedical and biological sciences.

For more information about the benefits of chartered engineering please contact Prof. Mike Hoare at [email protected].

For information on how MBI® Bioprocessing delegates can eventually gain Chartered Engineer status please contact Dr Karen Smith at [email protected].

7

8

Vision 2011 Senior Leadership Course

“Connectivity is our strength” The VISION programme aims to be the nexus for the leaders of the biological sciences industry to hear and debate the latest technological and business developments in the sector.

Our second run of the Senior Leadership Course took place on 18–20 May in the UCL Roberts Building Executive Suite. Thirteen senior industrial delegates spanning the SME, mid-size enterprise and large pharma sectors were joined by representatives from the National Skills Academy (Process Engineering) and the HealthTech and Medicines KTN. They heard thought-provoking and sometimes controversial talks from senior though-leaders drawn from across the bio-industries and they participated in a range of stimulating case studies and moderated round table sessions.

Day 1Pathfinder Session• Susan Dexter of Latham BiopharmManaging the next decade: Are you on track now? • Dr Steve Arlington, PwCNetworking Dinner•

Day 2Business Case Studies: a Toolbox for Strategy• Jonathon Marshall & Kate Moss, PwCLeadership: a Means to an End• Rahul Singhvi, NovavaxCan Biosimilars Innovate? • Professor Barry Buckland, BiologicBPatenting: What to Avoid and What to Embrace• Vicki Salmon, IP Asset LLPRound Table Discussion• Moderator Martyn Postle, Asia Healthcare & Biotech LtdCourse Dinner; After-dinner talk – ‘How to Say No – and How to Know When •to Say No’ Dr Neil Weir, UCB

Day 3Supply Chain – How to Handle Uncertainty • Ed Arcuri, AuxiliumBiopharmaceutical Partnering: Due Diligence – Case Study • Dr Michelle Scott, Unicorn Biologics

Our next Vision event will be held on 15 September 2011 and is a Business Briefing entitled Does QbD make business Sense? What new approaches to technology can make it a viable proposition? Speaker: Richard Francis.

For further information please contact Dr Karen Smith at [email protected] or Prof Eli Keshavarz-Moore at [email protected].

VISION supporters

9

Prof. Eli Keshavarz-Moore with Vicki Salmon and Michael Murray.

VISION delegates undertaking a case study.

VISION delegates in the Executive Suite.

10

Rahul Singhvi delivering his talk‘Leadership: a means to an end’.

Prof Nigel Titchener-Hooker in discussion with Susan Dexter (speaker)

and Vaughan Thomas (delegate).

Prof Steve Arlington delivering his talk ‘Managing the next decade: are you on track now?’.


Creating manufacturing innovations so as to deliver affordable next generation advanced therapies to the UK healthcare systemThe UCL Department of Biochemical Engineering has been awarded £4.9m to establish an EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies, in collaboration with partners at Imperial College and the London School of Pharmacy. Another £3.9m will be leveraged from industry over the life of the grant.

The EPSRC Centre will aim to deliver innovation in manufacturing research to assess emergent challenges facing the UK biopharmaceutical sector, and which impact its global competitiveness. It will act as the focus for a national network of leading users and academics in manufacturing and provide strong support for UK industry. It will become recognised as the primary centre for the creation, delivery and dissemination of decision-support tools to enable lifecycle optimisation of novel macromolecular therapies. This will widen access to valuable therapies for diseases such as severe arthritis, cancers which are currently untreatable and multiple sclerosis by raising manufacturing efficiency whilst reducing costs to the purchaser (e.g. NHS).

The current manufacturing model in the UK is rapidly becoming uncompetitive. While selection of the drug lead for development is primarily based on clinical efficacy, significant advantage can be gained from early analysis and development of the entire manufacturing pathway. Macromolecular medicines are complex products. They are more costly to manufacture and use than conventional chemical medicines. If the fit of the manufacturing process and design of the final medicine are poor, then costs will escalate and patient access will be restricted because of acute budget pressures on the NHS. The UK global position in pharmaceutical development will also suffer, as manufacturing practices will continue to migrate to regions where costs are low.

For more information about the Centre, please contact Prof. Nigel Titchener-Hooker at [email protected].

11

Project partners. Industry associations: ABPI, BIA, HealthTech & Medicines KTN. Companies: Aegis Analytical, Avacta, BioPharm Services, BTG Plc, Eli Lilly, Francis BioPharma Consulting, GE Healthcare, GlaxoSmithKline, Lonza Biologics, MedImmune, Merck & Co, MSD Biologics, Novo Nordisk, Novozymes Biopharma, Office of Health Economics (OHE), Pfizer, Syntaxin, The Automation Partnership (TAP), UCB Pharma. Government-related: Health Protection Agency, NIBSC, NHS QIPP.

Responsive Bioprocessing Facility – Planning for the FutureSingle-use technologies (SUTs) are an important addition to the bioprocess industry and our ability to understand new designs, evaluate their potential applications and identify limitations will prove to be an important aspect of their utilisation. Over the past ten years the single-use market place has become very crowded. New designs and innovations have led to various formats of bioreactors and downstream processes. Currently there are over 60 companies worldwide active in SUT processes and analytics; these companies have created novel designs and reinvented existing unit operations.

SUTs have several key advantages over established stainless steel. Speed of production and reduction in turnaround times can increase productivity by 30%. Furthermore, SUTs have the ability to rapidly expand in order to meet seasonal demands because of the flexible nature of their design and lower facilities requirements when compared to stainless steel.

But each new design requires engineering characterisation. Flow patterns, volume retentions, protein absorption onto the material of construction, hydrodynamic shear and mixing times all determine the productivity of the step. Additionally the choice of cell line, fusion protein product, virus or antibody could all have different binding and interaction effects within the SUT unit.

As part of the re-fit of its primary research facility, the Advanced Centre for Biochemical Engineering, we have recently created the Responsive Bioprocess Facility (RBF). This is a dedicated area committed to research, training and knowledge transfer of single-use technologies. Already we are working with several companies to help populate the area with new and interesting single-use units. Our desire is that this facility and the SUTs that it will contain are embedded into some of our existing MBI courses. It will also serve as an opportunity to train our undergraduates and Masters degree cohorts in the different operations, limitations and uses of SUTs when compared with traditional stainless steel facilities.

With such a dedicated facility there will be opportunities for research into operations and cost-based analysis of SUTs within existing PhD and EngD projects, but also for new projects. Depending on the level of company engagement one option might be to recruit a dedicated PDRA (Post-Doctoral Research Associate) for short (three-month) studies to produce a technical note, or perhaps longer (6–12 month projects) for an original publication. Our hope is to attract the attention of the single-use community for such research opportunities so that the department and its stakeholders can continue to meet the changing demands of the bioprocess industry.

For further information about the RBF, please contact Dr Tarit Mukhopadhyay at [email protected] or Dr Martina Micheletti at [email protected].

12

13

Bioprocess BriefingsBioprocess Briefings are regular events for the bioprocessing community in which seminars in recent bioprocessing research and development are given by high-profile speakers. They are very popular with audiences of more than 100 commonplace.They are followed by lively drinks receptions organised by the Beaker Society that provide the audiences with excellent networking opportunities and the chance to talk with speakers directly.

Bioprocess Briefings were designed as a component of the Innovative Manufacturing Research Centre for Bioprocessing (IMRC) to facilitate knowledge exchange. If an interested party is in or around the London area on a Briefing day, they can make the most of their trip by attending. Since the briefings started in January 2003 we have organised 63 Briefings.

The talks cover a wide range of topics from the manufacturing of advanced therapeutics such as DNA vaccines, antibody, and antibody fragments to fundamental understanding of cell properties and advanced analytical tools.

Our speakers are all international leaders in the bioprocessing field drawn from the biopharma and biotech industries and academia. Previous speakers have included Prof. Barry Buckland, ex-director of Bioprocessing R&D at Merck and now CEO of Biologic B; Dr. Jonathan Coffman, Wyeth BioPharm (now Pfizer); Prof. Conan J. Fee, Head of Department of Chemical Engineering, University of Canterbury, New Zealand; Prof. M. Nazmul Karim, Chair of Chemical Engineering, Texas Tech University; and Prof. Steve Cramer, Rensselaer Polytechnic Institute, USA.

The recent May Briefing was given by Dr Debora Iglesias-Rodriguez from the National Oceanography Centre, University of Southampton. She gave a fascinating talk about microbial biomineralization and its applications in geoengineering and carbon capture.

Dr Helen Mason from BP will talk about renewable biofuel research and development on 28 July.

For more information about our Bioprocess Briefings please contact Dr Yuhong Zhou at [email protected].

SME Engagement: Immbio Case StudyImmunoBiology Ltd (ImmBio) is a Cambridge-based SME company, working to develop novel anti-infective vaccines addressing areas of high unmet need. The company’s pipeline is based on two distinct technology platforms. The first, ImmBioVax™, replicates the innate stage of the immune response to safely create protection and contains antigens, heat shock proteins and antigenic proteins complexed to heat shock proteins. The second, ImmunoBodies™, consists of an antibody Fc-antigen fusion protein approach. Both technology platforms target antigen delivery to the dendritic cells of the immune system, which play a critical role in generating the immune responses necessary for successful protection against infectious agents. Rapid development of cost-effective, viable production processes is critical for the success of a biotechnology development organisation and particularly so for vaccine production. This need drove ImmBio’s initial collaboration with the ACBE, a joint Technology-Strategy-Board-funded project (Manufacture of low cost, high-efficacy vaccines) with Professor Mike Hoare. This project uses ACBE ultra scale-down (USD) approaches to predict process at scale for future ImmunoBody vaccines. The collaboration provided ImmBio with an introduction to the broad range of ACBE courses and collaborative opportunities open to Biotech Companies.

ImmBio’s management recognised the value of MBI® training modules to develop colleagues within the organisation. ImmBio’s Head of Laboratory, Claire Entwisle, now uses the MBI® scheme to provide essential training not possible at ImmBio. These training opportunities have to deliver real benefits to the organisation and must be cost-effective. This has already proven to be the case for Dr Kate Dalton, a senior ImmBio scientist, who has attended several MBI® modules. We then expanded our collaboration with the ACBE to include an EngD student, Eduardo Lau. This studentship strengthened links between ImmBio and the ACBE, particularly for Dr Ann McIlgorm, a senior scientist at ImmBio, and has already proved valuable as we develop new fusion protein production processes. The industry focus provided by the EngD training programme and the quality of students recruited provided ImmBio with a colleague who rapidly made significant positive impacts to the company. We have also taken an active role in the Industrial Training Advisory Board (ITAB), helping to ensure that the training delivered to students closely matches the present and future needs of Companies such as ours.

The breadth of contacts and depth of experience available to a company through the industrial network established by ACBE can prove invaluable. In one example, ImmBio identified an organisation, Novasep Process, and entered discussions to provide GMP production through an initial contact made at a recent ITAB meeting. Benefits have not been limited to technical developments; we have used the VISION programme to increase our knowledge of new business approaches and to provide access to ‘in-job’ development on topics such as IP and Alliance management. Individual collaborations and courses have proven to be beneficial to ImmBio and the presence of in house experts at the ACBE, such as Dr Tarit Mukhopadhyay, has proved of value to our business. However, it is the synergy generated through the diverse range of interactions and courses from TSB grant, EngD studentship, MBI® and Vision programmes that has proved to be most valuable to us.

For further information about opportunities to collaborate with UCL and the range of training courses available, please email Dr Karen Smith ([email protected]). For further information about ImmBio please contact Dr Shaun McNulty, [email protected], telephone: 01223 496122, or Graham Clarke (CEO), [email protected], telephone 01223 496117.

If you would like further details about EngD opportunities, the MBI® or Vision programmes please contact Dr Karen Smith at [email protected] in the first instance.

14

The MBI Training Programme is run by the Department and comprises a series of UCL-accredited short courses in bioprocessing, designed specifically for industrialists. They can be taken as stand-alone modules or can be combined for certificate, diploma or Masters qualifications. To date 1,000 modules have been taught to over 700 international delegates, and more than 200 companies have participated.

MBI® Module: Principles of Fermentation (3–5 October 2011)‘Principles of Fermentation Processes’ will strengthen your knowledge of fermentation processes, and through a series of lectures, case studies and a pilot plant visit, will enable you to:

Define different modes of fermentation and know their limitations. • Develop a suitable medium and perform a material balance. • Interpret fermentation data and use it effectively. • Characterise the kinetics of cell growth and how they apply to different cell systems. • Determine fermentation productivity and yields. • Understand the impact of microbial physiology on fermentation performance. • Develop a strategy for fermentation process development. •

The module consists of lectures from industrial and academic experts, and interactive problem-solving case studies performed in small groups for effective learning.

This module is suitable for scientists and engineers who wish to familiarise themselves with fermentation processes and those who wish to build underlying principles into their operational expertise in areas of research, process development and manufacturing.

Monday 3 OctoberEvaluation of different expression systems (Eli Keshavarz-Moore, UCL)•Fermentation Mass Balancing (Gary Lye, UCL)•Biomass Growth Kinetics (Frank Baganz, UCL)•Tour of facilities •

Tuesday 4 OctoberCase Studies in Growth Kinetics (Frank Baganz, UCL), Mass Balancing •(Gary Lye, UCL) and Fermentation Simulation (Frank Baganz, UCL)New Developments in Fermentation Technology (Grainne McDonagh, •BioPharm Services Ltd)Different Modes of Fermentation Operation (Frank Baganz, UCL) •Impact of Microbial Physiology on Fermentation (Colin Ratledge, Hull University) •

Wednesday 5 OctoberCase Study: Microbial Media Development (Gary Lye, UCL) •Introduction to Animal Cell Culture (Farlan Veraitch, UCL)•Present and Future Trends in Fermentation (James Mills, Cantabio) •

A networking dinner will be held on the first evening. The module costs £1300. Please contact [email protected] for further information.

15

MBI® course dates 2011–12Principles of Fermentation Processes: 3 – 5 October 2011Rapid Fermentation Process Design: 17 – 19 October 2011Challenges & Opportunities in Biocatalysis: 31 October – 2 November 2011Primary Recovery: 14 – 17 November 2011Chromatography: 28 November – 1 December 2011Vaccines: 14 – 16 December 2011Mammalian Cell Processes: 30 January – 1 February 2012Stem Cell and Regenerative Medicine Bioprocessing: 20 – 22 February 2012Quality by Design: 27 February – 1 March 2012Design of Experiments for Bioprocess Optimisation: 12 – 14 March 2012Effective Biopharmaceutical Development & Manufacture: 14 – 16 May 2012Bioprocess Design & Economic Evaluation: 11 – 14 June 2012Bioprocess Facility Design: 18 – 21 June 2012

For more information, email [email protected]

Work with usThe UCL Advanced Centre for Biochemical Engineering actively encourages and fosters long-term research partnerships between its academics and sponsors for mutual benefit. We facilitate interaction in a range of ways, such as sponsor visits, industrial advisory boards, Bioprocess Briefings, industrial placements for graduate students and the MBI® Programme. Over 70 industrial and academic experts contribute to our MBI® activities. If you would like further information, please contact the appropriate member of staff listed to the left.

16

ContactsResearch Sponsors and VISION: Dr Karen Smith Director of Bioprocess Leadership+44 (0)20 7679 [email protected]

MBI®: Miss Liz Barrett MBI® Manager+44 (0)20 7679 [email protected]

EPSRC Centre for Macromolecular TherapiesProfessor Nigel Titchener-Hooker+44 (0)20 7679 3796

IMRC for BioprocessingProfessor Mike Hoare+44 (0)20 7679 [email protected]

BiCE, Engineering Doctorate in Bioprocess Leadership and Industrial Doctoral Training Centre for Bioprocess Leadership (IDTC) Professor Gary Lye+44 (0)20 7679 [email protected]

RegenMed BioprocessingProfessor Chris Mason+44 (0)20 7679 [email protected]

bioprocessing matters, august 2011 - university college · pdf fileconditions within a...

Documents